Rybrevant

Active Ingredient(s): Amivantamab-vmjw
FDA Approved: * May 21, 2021
Pharm Company: * JANSSEN BIOTECH
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Rybrevant Overview

Amivantamab, sold under the brand name Rybrevant, is a monoclonal antibody medication used to treat non-small cell lung cancer.[1][2][3] The most common side effects include rash, infusion-related reactions, skin infections around the fingernails or toenails, muscle and joint pain, shortness of breath, nausea, fatigue, swelling in the lower legs or hands or face, sores in the mouth, cough, constipation, vomiting and changes in certain blood test...

Read more Rybrevant Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Amivantamab

Recent Rybrevant Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Amivantamab-vmjw
  • Injection: 350mg/7ml(50mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Rybrevant: (1 result)

Sorted by National Drug Code
  • 57894-501 Rybrevant 350 mg Intravenous Injection by Janssen Biotech, Inc.

Other drugs which contain Amivantamab-vmjw or a similar ingredient: (1 result)